Healthcare Industry News:  cardiopulmonary 

Devices Cardiology

 News Release - February 21, 2011

Sorin Group Announces the Achievement of a Key Milestone in Aortic Valve Replacement

More than 100,000 Mitroflow(TM) Aortic Pericardial Heart Valves Implanted Worldwide

MILAN--(Healthcare Sales & Marketing Network)-- Sorin Group, (Reuters Code: SORN.MI) (MIL:SRN.mi ), a global medical device company and a leader in the treatment of cardiovascular diseases, announced a major milestone today: more than 100,000 Mitroflow Aortic Pericardial Heart Valves have now been implanted worldwide.

Today some six million patients worldwide suffer from aortic valve diseases. Aortic valve replacement is the most effective treatment for this condition, improving survival rates and quality of life. Indeed, the Mitroflow pericardial valve is able to fully replace a malfunctioning or diseased aortic heart valve, offering an effective choice for patients and surgeons.

Since its market introduction in Europe in 1982, Sorin’s Mitroflow Aortic Pericardial Heart Valve has demonstrated excellent hemodynamic performance and proven long-term durability. Due to its unique design, supported by nearly 30 years of clinical use and 21 years of published long-term results, the Mitroflow valve is recognized by surgeons worldwide for its versatility and ease of implant, even in the most challenging anatomies.

"Our clinical experience with over 1,900 implants with the Mitroflow Aortic Pericardial Heart Valve has shown the valve’s exceptional durability, one of the longest on the market. This can be attributed to its special design, easy implantability and excellent hemodynamic characteristics. Mitroflow has provided assurance to a wide variety of patients who prefer or require biological valve implantation” said Prof. Charles Yankah, Associate Professor of Surgery, Charité Medical University and Consultant CardioThoracic and Vascular Surgeon, German Heart Institute in Berlin, Germany.

“We are extremely pleased to have reached and exceeded this outstanding milestone”, said Davide Bianchi, Sorin Group President Heart Valve Business Unit. “This confirms once again that the Mitroflow valve, with its outstanding hemodynamics and durability, is an excellent option for aortic valve replacement. These positive results will further encourage us to keep offering this state-of the-art valve to cardiac surgeons and patients worldwide.”

About Sorin Group

Sorin Group (www.sorin.com), is a global medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,600 employees worldwide, Sorin Group focuses on three major therapeutic areas that include cardiopulmonary bypass (extracorporeal circulation and autotransfusion systems), cardiac rhythm management, and heart valve repair and replacement. Every year, over one million patients are treated with Sorin Group devices in more than 80 countries.

For more information, please visit: www.sorin.com


Source: Sorin Group

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.